Outcome of patients with refractory/relapsed aml salvaged with the mec (mitoxantrone etoposide cytarabine) regimen

C. Castagnola, E. P. Alessandrino, G. Pagnucco, P. Bernasconi, M. Lunghi, A. Colombo, E. Brusamolino, M. Bonfichi, A. Corso, M. Lazzarino, C. Bernasconi

Research output: Contribution to journalArticle

Abstract

Thirty-three patients with acute myeloid leukemia (AML), median age 36 years (range 19-59), treated with the MEC regimen as salvage therapy for refractory or relapsed disease were analyzed for long term outcome. Characteristics: 10 primary refractory, 9 early relapse (ie, remission l,000/mL and platelet >50,000/mL was 29 and 24 days respectively. Myelosuppression and infection were the major toxicities. Extrahematologic toxicity was mild or moderate, consisting mostly of nausea and vomiting, oral mucositis and transient liver or cardiac dysfunction. Multivariate analysis showed the type of resistance as the only factor affecting response: 79% CR rate in patients with a first CR lasting >6 months versus 20% in refractory AML and 33% in AML relapsed within 6 months (p

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART II
Publication statusPublished - 2000

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Castagnola, C., Alessandrino, E. P., Pagnucco, G., Bernasconi, P., Lunghi, M., Colombo, A., Brusamolino, E., Bonfichi, M., Corso, A., Lazzarino, M., & Bernasconi, C. (2000). Outcome of patients with refractory/relapsed aml salvaged with the mec (mitoxantrone etoposide cytarabine) regimen. Blood, 96(11 PART II).